CAMP4 Therapeutics (CAMP) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
CAMP4 Therapeutics (CAMP) has outperformed Upstream Bio (UPB) over the past year, gaining 16.7% versus a loss of 75.3%. Upstream Bio is the larger company by market cap ($252.5 million vs $241.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAMP | UPB |
|---|---|---|
| Share price | $3.84 | $4.61 |
| Market cap | $240.97M | $252.49M |
| 1-day change | -3.03% | +0.44% |
| YTD return | -37.36% | -83.02% |
| 1-year return | +16.72% | -75.31% |
| EPS (TTM) | $-2.32 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $33.68 |
| 52-week low | $2.86 | $4.50 |
| Distance from 52-week high | -50.45% | -86.31% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +175.26% | +575.49% |
| Average volume | 279.95K | 605.35K |
| Shares outstanding | 62.75M | 54.77M |
| Employees | 48 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CAMP has outperformed UPB by 92.0 percentage points over the past year.
About CAMP4 Therapeutics
CAMP stock →Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
CAMP vs UPB FAQ
Which is bigger, CAMP4 Therapeutics or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $252.49M compared with $240.97M for CAMP4 Therapeutics (CAMP).
Which stock has performed better over the past year, CAMP or UPB?
CAMP returned +16.72% over the past 12 months, compared with -75.31% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are CAMP4 Therapeutics and Upstream Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.